Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, Miyakawa J, Nakamura Y, Hoshina H, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Adachi Y, Sugimoto K, Sato K, Tabata M, Tanaka T, Nara K, Uemura Y, Kamei J, Akiyama Y, Sato Y, Yamada Y, Niimi A, Yamada D, Takada T, Takahashi S, Yamada Y, Miyazaki H, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H.
Taguchi S, et al. Among authors: adachi y.
Int J Urol. 2024 Nov 22. doi: 10.1111/iju.15640. Online ahead of print.
Int J Urol. 2024.
PMID: 39575880